Commercialization of cell therapies – biopreservation’s make or break impact: an interview with Mike Rice
Mike Rice, CEO of NASDAQ traded BioLifeSolutions (WA, USA) explains the importance of biopreservation in commercializing regenerative medicine therapies and why funding for new cell-based therapies remains high.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>